Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...

This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

We expect Amgen AMGN to beat expectations when it reports fourth-quarter and full-year 2024 results on Feb. 4, after market ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...